Real-world baseline characteristics and first-line (1L) treatment (Tx) in patients (pts) with de novo metastatic castration-sensitive prostate cancer (mCSPC) by disease volume.

被引：0
|
作者：
Freedland, Stephen J.
Hong, Agnes
El-Chaar, Nader N.
De Hoedt, Amanda Marie
Kim, Janet
Ramaswamy, Krishnan
Gu, Lin
Polascik, Thomas
机构：
[1] Cedars Sinai Med Ctr, Ctr Integrated Res Canc & Lifestyle, Los Angeles, CA USA
[2] Astellas Pharma Inc, Northbrook, IL USA
[3] Pfizer Inc, New York, NY USA
[4] Vet Affairs Hlth Care Syst, Urol Sect, Dept Surg, Durham, NC USA
[5] Astellas Pharma Global Dev Inc, Northbrook, IL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e17081
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Genomic characterization of patients (pts) with de-novo high-volume metastatic castration-sensitive prostate cancer (dn-hv-mCSPC) compared to those without dn-hv-mCSPC.
    Sayegh, Nicolas
    Jo, Yeonjung
    Tripathi, Nishita
    McFarland, Taylor Ryan
    Kessel, Adam
    Nussenzveig, Roberto
    Chigarira, Beverly
    Li, Haoran
    Tandar, Clara
    Sahu, Kamal Kant
    Haaland, Benjamin
    Maughan, Benjamin L.
    Swami, Umang
    Agarwal, Neeraj
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [22] Real-world (RW) comparison of prostate-specific antigen (PSA) response in patients with de novo metastatic castration-sensitive prostate cancer (mCSPC) treated with apalutamide (APA) versus enzalutamide (ENZ)
    Lowentritt, Benjamin H.
    Khilfeh, Ibrahim
    Pilon, Dominic
    Du, Shawn
    Rossi, Carmine
    Kinkead, Frederic
    Diaz, Lilian
    Ellis, Lorie
    Lefebvre, Patrick
    Brown, Gordon Andrew
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [23] Real-world utilization of advanced therapies by metastatic site and age among patients with metastatic castration-sensitive prostate cancer (mCSPC): A Medicare database analysis
    George, D. J.
    Agarwal, N.
    Ramaswamy, K.
    Sandin, R.
    Russell, D.
    Hong, A.
    Yang, H.
    Gao, W.
    Hagan, K.
    Freedland, S. J.
    ANNALS OF ONCOLOGY, 2021, 32 : S655 - S656
  • [24] Management of Patients with Metastatic Castration-Sensitive Prostate Cancer in the Real-World Setting in the United States
    Ryan, Charles J.
    Ke, Xuehua
    Lafeuille, Marie-Helene
    Romdhani, Hela
    Kinkead, Frederic
    Lefebvre, Patrick
    Petrilla, Allison
    Pulungan, Zul
    Kim, Seung
    D'Andrea, Denise M.
    Francis, Peter
    Freedland, Stephen J.
    JOURNAL OF UROLOGY, 2021, 206 (06): : 1420 - 1429
  • [25] Real-world (RW) treatment (Tx) patterns and clinical outcomes in patients (pts) with metastatic urothelial carcinoma (mUC) receiving first-line (1L) Tx: Results from IMPACT UC
    Bilen, M. A.
    Xi, A. D.
    Wong, A.
    Schroeder, A.
    Kim, R.
    Liu, F. X.
    Peng, J.
    Robinson, S.
    Bhanegaonkar, A.
    ANNALS OF ONCOLOGY, 2021, 32 : S713 - S713
  • [26] Management of Patients with Metastatic Castration-Sensitive Prostate Cancer in the Real-World Setting in the United States
    Schiff, Howard I.
    JOURNAL OF UROLOGY, 2022, 207 (04): : 939 - 939
  • [27] Underutilization of standard of care (SOC) treatment intensification in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) by specialty.
    Swami, Umang
    Hong, Agnes
    El-Chaar, Nader N.
    Nimke, David
    Ramaswamy, Krishnan
    Diessner, Brandon
    Sandin, Rickard
    Agarwal, Neeraj
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [28] Real-World Outcomes in First-Line Treatment of Metastatic Castration-Resistant Prostate Cancer: The Prostate Cancer Registry
    Simon Chowdhury
    Anders Bjartell
    Nicolaas Lumen
    Pablo Maroto
    Thomas Paiss
    Francisco Gomez-Veiga
    Alison Birtle
    Gero Kramer
    Ewa Kalinka
    Dominique Spaëth
    Susan Feyerabend
    Vsevolod Matveev
    Florence Lefresne
    Martin Lukac
    Robert Wapenaar
    Luis Costa
    Targeted Oncology, 2020, 15 : 301 - 315
  • [29] Real-World Outcomes in First-Line Treatment of Metastatic Castration-Resistant Prostate Cancer: The Prostate Cancer Registry
    Chowdhury, Simon
    Bjartell, Anders
    Lumen, Nicolaas
    Maroto, Pablo
    Paiss, Thomas
    Gomez-Veiga, Francisco
    Birtle, Alison
    Kramer, Gero
    Kalinka, Ewa
    Spaeth, Dominique
    Feyerabend, Susan
    Matveev, Vsevolod
    Lefresne, Florence
    Lukac, Martin
    Wapenaarls, Robert
    Costa, Luis
    TARGETED ONCOLOGY, 2020, 15 (03) : 301 - 315
  • [30] Real-world treatment (Tx) patterns of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) in the US
    Shore, N.
    Laliberte, F.
    Ionescu-Ittu, R.
    Gayle, A.
    Amin, S.
    Yang, L.
    Payne, S.
    Mahendran, M.
    Lejeune, D.
    Yu, L.
    Burgents, J.
    Duh, M. S.
    Ghate, S.
    ANNALS OF ONCOLOGY, 2020, 31 : S534 - S535
12345